Isogenica develops VHH, versatile antibodies for multi-specifics, ADCs, cell and gene therapies.
Single Domain Biotherapeutics
Isogenica develops highly versatile, small-format VHH antibodies which we use to construct next generation biotherapeutics for the treatment of cancer, inflammation, and other serious diseases.
VHH can be assembled to create multi-specific biotherapeutics or used to achieve targeted drug delivery as components of ADCs and cell therapies including CAR-Ts.
We are leaders in antibody discovery and engineering. Drawing on our 20 years of expertise and knowledge, we have built a unique and proven engine for biotherapeutic development and our own deep pipeline including two clinical stage assets.
Meet our Team
Our experienced team learned their craft at Ablynx, Bicycle Therapeutics, Roche and other leading biopharma.